PLC ("4basebio" or the "Company") 4basebio Launches Enzymatic ssDNA Platform Overcomes critical manufacturing and performance bottlenecks associated with traditional chemical synthesis, providing ...

May 2026 – 4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces the commercial launch of its high-capacity single-stranded ...

It’s hard to imagine that a snail could kill a person, but a particularly venomous group of marine molluscs called cone ...

Richard Bungay appointed as CFO, bringing a strong track record in fundraising, M&A and partnering for listed and private companies, including two major exits and over $400m raisedCambridge, UK, 14 ...

Appointment of Chief Financial Officer and Board Changes · Richard Bungay appointed as CFO, bringing a strong track record in fundraising, M&A and partnering for listed and private companies, ...

We appreciate you taking the time out of your busy schedules to attend our Investors Meeting for FY 2025 financial results, management priorities and business strategies. Today's session will begin ...

Zhejiang Hengkang Pharmaceutical Co., Ltd. continues to strengthen its position as a leading manufacturer within the global active pharmaceutical ingredient industry, attracting growing attention for ...

Hongene Biotech shows advanced oligonucleotide CDMO capabilities via support of SiranBio’s dual-target siRNA programme: Singapore Saturday, May 9, 2026, 16:00 Hrs [IST] Hongene ...

Genomics and Harvard University have sued Element Biosciences, alleging that Element’s AVITI24™ multiomics platform, Teton ...

I n December 2020, mRNA vaccines leapt into the limelight as a response to the COVID-19 pandemic. To date, millions of people ...

The oligonucleotides clinical trial analysis report delivers important insights into ongoing research on 600+ ...

Research and Development expenses for the first quarter of 2026 were $11.4 million compared to $12.9 million in the first quarter of 2025. The decrease was primarily due to lower allocable costs, ...